SMARCA1 and non-small cell lung carcinoma: In patients with NSCLC and low PD-L1 scores (<50), the mPFS of patients with any SWI/SNF complex mutation was superior to that of WT patients treated with ICIs (8.3 vs. 3.7 months; P = 0.001; HR = 0.420; 95% CI = 0.246–0.717; Supplementary Figure 3B).